__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Efficacy of LUCENTIS in different ophthalmic indications.
Indications1
LUCENTIS 0.5 mg is indicated in adults for:
- The treatment of neovascular (wet) age-related macular degeneration (AMD)
- The treatment of visual impairment due to diabetic macular oedema (DMO)
- The treatment of proliferative diabetic retinopathy (PDR)
- The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
- The treatment of visual impairment due to choroidal neovascularisation (CNV).
LUCENTIS 0.2 mg is indicated in preterm infants for:
- The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
AMD, age-related macular degeneration; DMO, diabetic macular oedema; ROP, retinopathy of prematurity.
Reference
- LUCENTIS® (ranibizumab) Summary of Product Characteristics, July 2020.
Key clinical study and real-world efficacy data for LUCENTIS® in the treatment of wet AMD.
Key efficacy data for LUCENTIS in the treatment of visual impairment due to DMO.Show more
Key efficacy data for LUCENTIS 0.2 mg in the treatment of ROP.